Cardiovascular disease and abdominal surgery Surgery Cardiovascular disease and abdominal surgery
Conditions
Interventions
In the operating theatre, participants are randomised to one of two groups using envelope randomisation.
Group 1: Participants receive fentanyl in a bolus of 3 mcg/kg after 1 minute o
Sponsors
University Medical Centre Maribor
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 50 years and over 2. ASA II-III 3. Patients scheduled for major abdominal surgery
Exclusion criteria
Exclusion criteria: 1. Heart failure (known ejection fraction less than 30%) 2. Manifest liver disease 3. Kidney disease (serum creatinine more than 120 mmol/L) 4. BMI more than 30 5. Anticipated difficult intubation (Mallampati score 3 and 4) 6. Drug abuse (including alcohol) 7. Chronic use of benzodiazepines, opioids or other psychotropic substances
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Current primary outcome measures as of 24/11/2021: 1. Cardiac output is measured using a LiDCOrapid monitor at baseline and for 15 minutes during the induction of anaesthesia 2. Mean arterial pressure is measured using a LiDCOrapid monitor at baseline and for 15 minutes during the induction of anaesthesia Previous primary outcome measures: 1. Cardiac output is measured using a LiDCOrapid monitor at baseline and for 15 minutes during the induction of anaesthesia 2. Stroke volume is measured using a LiDCOrapid monitor at baseline and for 15 minutes during the induction of anaesthesia 3. Mean arterial pressure is measured using a LiDCOrapid monitor at baseline and for 15 minutes during the induction of anaesthesia | — |
Secondary
| Measure | Time frame |
|---|---|
| Current secondary outcome measures as of 24/11/2021: 1. Heart rate is measured using a LiDCOrapid monitor at baseline and for 15 minutes during the induction of anaesthesia 2. Stroke volume is measured using a LiDCOrapid monitor at baseline and for 15 minutes during the induction of anaesthesia 3. Systemic vascular resistance is measured using a LiDCOrapid monitor at baseline and for 15 minutes during the induction of anaesthesia 4. Stroke volume variation is measured using a LiDCOrapid monitor at baseline and for 15 minutes during the induction of anaesthesia. 5. Dose of propofol is measured at the end of induction (the cumulative dose is given on the perfusor screen) 6. Time from the start of anaesthesia induction to laryngoscopy and intubation is measured for each patient using the timer on the screen of the anaesthesia machine 7. Potential rescue management is recorded for each patient at the end of induction 8. Doses of drugs needed is calculated at the end of induction for each patient Previous secondary outcome measures: 1. Heart rate is measured using a LiDCOrapid monitor at baseline and for 15 minutes during the induction of anaesthesia 2. Systemic vascular resistance is measured using a LiDCOrapid monitor at baseline and for 15 minutes during the induction of anaesthesia 3. Bispectral index is measured using a LiDCOrapid monitor at baseline and for 15 minutes during the induction of anaesthesia 4. Dose of propofol is measured at the end of induction (the cumulative dose is given on the perfusor screen) 5. Time from start of anaesthesia induction to laryngoscopy and intubation is measured for each patient using the timer on the screen of the anaesthesia machine 6. Potential rescue management is recorded for each patient | — |
Countries
Slovenia
Outcome results
None listed